Peningkatan profil klinik-hematologi pada pasien sindrom mielodisplasia multilini paska splenektomi total

Authors

  • Siswi Oktariani Trainee, Divisi Hematologi dan Onkologi Medis, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia
  • Adeodatus Yuda Handaya Divisi Bedah Digestif, Bagian Ilmu Penyakit Bedah, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia
  • Ibnu Purwanto Divisi Hematologi dan Onkologi Medik, Bagian Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

DOI:

https://doi.org/10.36216/jpd.v4i1.133

Keywords:

myelodysplasia syndrome, splenomegali, splenektomi

Abstract

Myelodysplasia syndrome (MDS) is a hematologic disorder manifested by cytopenia and rarely with splenomegaly. Clinical complaints that often accompany symptoms of anemia and when experiencing splenomegaly, the patient feels a full stomach or sometimes pain in the upper left abdomen. We report a case of a 55 year old woman with a full stomach complaint with a history of thrombocytopenia. From the peripheral blood examination, observation of thrombocytopenia was obtained with suspicion of the inflammatory process and physical examination of splenomegaly. Bone marrow aspiration studies revealed a multi-line cytopenic refractory MDS. Patients receive immunosuppressant therapy without blood transfusions. After 1 year of treatment the patient complained of fatigue and upper left abdominal pain. The results showed pancytopenia and splenomegaly. The doctor and patient discussion agreed to the splenectomy. The patient had no complications after splenectomy and for 11 months the patient felt complaint free and normal hematological parameters with a good quality of life. This case report suggests that splenectomy can be an alternative therapy for MDS that is refractory to previous therapy and is complaining of splenomegaly. Splenectomy can improve the clinical complaints and hematologic profile of MDS patients with splenomegaly.

Downloads

Download data is not yet available.

Author Biographies

Siswi Oktariani, Trainee, Divisi Hematologi dan Onkologi Medis, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

Trainee, Divisi Hematologi dan Onkologi Medis, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

Adeodatus Yuda Handaya, Divisi Bedah Digestif, Bagian Ilmu Penyakit Bedah, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

Divisi Bedah Digestif, Bagian Ilmu Penyakit Bedah, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

Ibnu Purwanto, Divisi Hematologi dan Onkologi Medik, Bagian Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

Divisi Hematologi dan Onkologi Medik, Bagian Ilmu Penyakit Dalam, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada / Rumah Sakit Dr.Sardjito, Yogyakarta, 55281, Indonesia

References

Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer Journal. 2018;8(47).

Nalluru SS., Jindal V, Piranavan P. et al. Splenic infarction secondary to myelodysplastic syndrome: unravelling more etiologies. AME Case Rep. 2019;3:31.

Kraus MD. Splenic histology and histopathology: an update. Semin Diagn Pathol. 2003;20(2):84-93.

Shimomura Y, Hara M, Katoh D, dkk. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2018;97(6):1049-1056.

Bourgeois E, Caulier MT, Rose C, dkk. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia. 2001;15(6):950-953.

Bickenbach KA, Gonen M, Labow DM, dkk. Indications for and efficacy of splenectomy for haematological disorders. Br J Surg. 2013;100:794–800.

Rialon KL, Speicher PJ, Ceppa EP, dkk. Outcomes following splenectomy in patients with myeloid neoplasms. J Surg Oncol . 2015 Mar 15;111(4):389-95

Weledji P. Benefits and risks of splenectomy. Int J Surg . 2014;12(2):113-119

Kokhno AV, Mikhailova EA, Parovichnikova EN, dkk. Splenectomy in Patients with MDS. Blood. 2010;116(21):1879.

Uchida R, Nakano S, Namura K, dkk. Is splenectomy a contraindication for patients with myelodysplastic syndromes complicated by splenomegaly?. Ann Hematol. 2006;85(3):198-199.

Published

2020-06-20

How to Cite

1.
Oktariani S, Handaya AY, Purwanto I. Peningkatan profil klinik-hematologi pada pasien sindrom mielodisplasia multilini paska splenektomi total . Udayana In. Med. [Internet]. 2020Jun.20 [cited 2021Mar.2];4(1):1-4. Available from: https://jpdunud.org/index.php/JPD/article/view/133